Developer docs
API playgroundTry for free, no card

Search company profiles

Institut Biochimique

Full company profile

uuid000vna3

Namestring
Institut Biochimique
Legal namestring
IBSA Institut Biochimique SA
Websiteurl
ibsa.swiss
Company typeenum
Private
Founded yearint
1945
Descriptiontext

IBSA Institut Biochimique SA is a privately held Swiss pharmaceutical company headquartered in Lugano, Switzerland, founded in 1945 by Arturo Licenziati. The company develops formulation-optimized dosage forms of already-known active ingredients and operates across ten therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular medicine, aesthetic medicine, dermatology, uro-gynecology, cardiometabolic medicine, respiratory system, and consumer health. Production is anchored in Switzerland (Lugano-Pazzallo headquarters and Cadempino business-operations site), with Swiss manufacturing positioned as a quality signal in regulated markets.

The company's go-to-market is a wholly-owned direct distribution model: IBSA operates 20 subsidiaries spanning Europe (Austria, Baltic States/Nordic, Belgium, Czechia, France, Germany, Hungary, Iberia, Italy, Netherlands, Poland, Slovakia, Switzerland, Turkey, UK), Asia (China, Hong Kong, Singapore), and the USA. Products are present in 90+ countries across five continents, including the Middle East, Far East, and North Africa. The firm employs more than 2,500 people globally and serves healthcare providers (physicians and specialists) and patients across each therapeutic area, with a horizontal segmentation strategy that emphasizes breadth of portfolio rather than concentration in any single category.

Revenue is generated primarily through one-time sales of pharmaceutical products; pricing is not publicly disclosed. Marketing is supported by the IBSA Foundation (scientific research grants and fertility-awareness campaigns), recurring branded events such as Coppa IBSA and StraLugano, and sponsorships including Casa dell'Hockey. The company operates a sustainability manifesto aligned with ESG objectives. No public-ownership, external-investor, or funding-round information is disclosed, and no M&A or restructuring activity is reported in the available data.

Short descriptiontext

IBSA is a privately held Swiss pharmaceutical company founded in 1945 that develops formulation-optimized dosage forms across ten therapeutic areas and distributes them in 90+ countries via 20 wholly-owned subsidiaries, employing more than 2,500 people globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLugano, Switzerland
HQ citystring
Lugano
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, reproductive medicine, endocrinology treatments, aesthetic medicine, consumer health products
Industry1 code
PRIMARYHLAAAKAB
Drug Product Fill-Finish & Aseptic Manufacturing Services
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceutical Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Products
TypeOne Time License
Description

Revenue generated from manufacturing and selling pharmaceutical products across 10 therapeutic areas including reproductive medicine, endocrinology, pain/inflammation, aesthetic medicine, dermatology, and consumer health.

ibsaswitzerland.ch
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

IBSA (Institut Biochimique SA) is a multinational Swiss pharmaceutical company that develops, manufactures, and distributes formulation-optimized dosage forms of already known active ingredients across 10 therapeutic areas, including reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynecology, cardiometabolic medicine, respiratory treatments, and consumer health. The company produces its pharmaceutical products in Switzerland and sells them through 20 wholly-owned subsidiaries to customers in 90+ countries.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

IBSA (Institut Biochimique SA) is a multinational Swiss pharmaceutical company founded in 1945, operating across 10 therapy areas. The company's product portfolio spans reproductive medicine, endocrinology, pain and inflammation management, bone and joint medicine, aesthetic medicine, dermatology, uro-gynecology, cardiometabolic conditions, respiratory treatments, and consumer health. The company serves over 90 countries with 20 subsidiaries in Europe, China, and the USA, employing more than 2,500 people worldwide.

Product and service1 record
1Reproductive Medicine
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Private Swiss specialty pharma headquartered near Lausanne with a heavy focus on reproductive medicine, uro-gynecology, and endocrinology — closely overlapping with IBSA's reproductive medicine, endocrinology, and uro-gynecology therapy areas and its direct-subsidiary European distribution model.

TypeDirect peer
Description

Women's-health-focused pharma spun out of Merck, with franchises in reproductive health, dermatology, and respiratory — directly overlapping with IBSA's reproductive medicine, dermatology, and respiratory therapy areas.

TypeDirect peer
Description

Hungarian specialty pharma with strong women's health, CNS, and cardiometabolic franchises — directly overlapping IBSA's reproductive medicine, endocrinology, and cardiometabolic therapy areas with a similar mid-size European footprint.

TypeBroad incumbent
Description

Global generics and specialty pharma formed from Mylan and Upjohn, with broad off-patent portfolio that directly competes with IBSA's reformulation-led approach across multiple therapy areas.

TypeDirect peer
Description

Spanish specialty pharma with focus on dermatology and aesthetic medicine, both of which are core IBSA therapy areas. Mid-cap European pharma with comparable portfolio breadth and geographic reach.

6Sandoz (Novartis)
TypeBroad incumbent
Description

Global generics and biosimilars business carved out of Novartis, offering broad formulation expertise across therapy areas overlapping with IBSA's portfolio, but operating at much larger scale and global reach.

TypeRegional player
Description

South African-headquartered specialty and generics pharma with emerging-market focus and broad therapeutic-area portfolio — comparable business model and scale to IBSA but primarily serves African and Asia-Pacific geographies rather than Europe/China/US.

TypeBroad incumbent
Description

Global generics and specialty leader with broad portfolio and large-scale manufacturing — competes with IBSA in formulation-improved generics and specialty pharma across overlapping therapy areas, but at vastly greater scale.

TypeDirect peer
Description

Privately-held German mid-size pharma with broad specialty and generics portfolio across multiple therapy areas and direct European country subsidiaries — closely mirrors IBSA's privately-held, multi-therapy, subsidiary-led model.

TypeDirect peer
Description

Milan-based specialty pharma operating across multiple therapeutic areas including cardiometabolic and rare diseases, with a similarly diversified mid-size portfolio and European commercial footprint comparable to IBSA's structure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries18 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Institut Biochimique

Pharmaceutical Manufacturingibsa.swiss

IBSA is a privately held Swiss pharmaceutical company founded in 1945 that develops formulation-optimized dosage forms across ten therapeutic areas and distributes them in 90+ countries via 20 wholly-owned subsidiaries, employing more than 2,500 people globally.

What Institut Biochimique does

IBSA Institut Biochimique SA is a privately held Swiss pharmaceutical company headquartered in Lugano, Switzerland, founded in 1945 by Arturo Licenziati. The company develops formulation-optimized dosage forms of already-known active ingredients and operates across ten therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular medicine, aesthetic medicine, dermatology, uro-gynecology, cardiometabolic medicine, respiratory system, and consumer health. Production is anchored in Switzerland (Lugano-Pazzallo headquarters and Cadempino business-operations site), with Swiss manufacturing positioned as a quality signal in regulated markets.

The company's go-to-market is a wholly-owned direct distribution model: IBSA operates 20 subsidiaries spanning Europe (Austria, Baltic States/Nordic, Belgium, Czechia, France, Germany, Hungary, Iberia, Italy, Netherlands, Poland, Slovakia, Switzerland, Turkey, UK), Asia (China, Hong Kong, Singapore), and the USA. Products are present in 90+ countries across five continents, including the Middle East, Far East, and North Africa. The firm employs more than 2,500 people globally and serves healthcare providers (physicians and specialists) and patients across each therapeutic area, with a horizontal segmentation strategy that emphasizes breadth of portfolio rather than concentration in any single category.

Revenue is generated primarily through one-time sales of pharmaceutical products; pricing is not publicly disclosed. Marketing is supported by the IBSA Foundation (scientific research grants and fertility-awareness campaigns), recurring branded events such as Coppa IBSA and StraLugano, and sponsorships including Casa dell'Hockey. The company operates a sustainability manifesto aligned with ESG objectives. No public-ownership, external-investor, or funding-round information is disclosed, and no M&A or restructuring activity is reported in the available data.

Institut Biochimique firmographics

Firmographics
Name
Institut Biochimique
Legal name
IBSA Institut Biochimique SA
Website
https://ibsa.swiss
Company type
Private
Founded year
1945
Operating status
Operating
Headcount range
101–250 employees
Short description
IBSA is a privately held Swiss pharmaceutical company founded in 1945 that develops formulation-optimized dosage forms across ten therapeutic areas and distributes them in 90+ countries via 20 wholly-owned subsidiaries, employing more than 2,500 people globally.
Ownership category
akta.pro rank

Institut Biochimique industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAKAB
Drug Product Fill-Finish & Aseptic Manufacturing Services

Keywords

  • Pharmaceutical manufacturing
  • Reproductive medicine
  • Endocrinology treatments
  • Aesthetic medicine
  • Consumer health products

Where Institut Biochimique is headquartered

Location

Headquarters

HQ city
Lugano
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Institut Biochimique business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical Products: Revenue generated from manufacturing and selling pharmaceutical products across 10 therapeutic areas including reproductive medicine, endocrinology, pain/inflammation, aesthetic medicine, dermatology, and consumer health.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Institut Biochimique product offering

Product offering

Core offering

IBSA (Institut Biochimique SA) is a multinational Swiss pharmaceutical company that develops, manufactures, and distributes formulation-optimized dosage forms of already known active ingredients across 10 therapeutic areas, including reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynecology, cardiometabolic medicine, respiratory treatments, and consumer health. The company produces its pharmaceutical products in Switzerland and sells them through 20 wholly-owned subsidiaries to customers in 90+ countries.

Product overview

IBSA (Institut Biochimique SA) is a multinational Swiss pharmaceutical company founded in 1945, operating across 10 therapy areas. The company's product portfolio spans reproductive medicine, endocrinology, pain and inflammation management, bone and joint medicine, aesthetic medicine, dermatology, uro-gynecology, cardiometabolic conditions, respiratory treatments, and consumer health. The company serves over 90 countries with 20 subsidiaries in Europe, China, and the USA, employing more than 2,500 people worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • Reproductive Medicine

Companies that use Institut Biochimique

Customer profile

Segments1 record

Ideal customer profiles1 record

Institut Biochimique technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Institut Biochimique partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Institut Biochimique competitors and assessment

Company assessment

Direct peers

  • Ferring Pharmaceuticals: Private Swiss specialty pharma headquartered near Lausanne with a heavy focus on reproductive medicine, uro-gynecology, and endocrinology — closely overlapping with IBSA's reproductive medicine, endocrinology, and uro-gynecology therapy areas and its direct-subsidiary European distribution model.
  • Organon: Women's-health-focused pharma spun out of Merck, with franchises in reproductive health, dermatology, and respiratory — directly overlapping with IBSA's reproductive medicine, dermatology, and respiratory therapy areas.
  • Gedeon Richter: Hungarian specialty pharma with strong women's health, CNS, and cardiometabolic franchises — directly overlapping IBSA's reproductive medicine, endocrinology, and cardiometabolic therapy areas with a similar mid-size European footprint.
  • Almirall: Spanish specialty pharma with focus on dermatology and aesthetic medicine, both of which are core IBSA therapy areas. Mid-cap European pharma with comparable portfolio breadth and geographic reach.
  • Stada Arzneimittel: Privately-held German mid-size pharma with broad specialty and generics portfolio across multiple therapy areas and direct European country subsidiaries — closely mirrors IBSA's privately-held, multi-therapy, subsidiary-led model.
  • Recordati: Milan-based specialty pharma operating across multiple therapeutic areas including cardiometabolic and rare diseases, with a similarly diversified mid-size portfolio and European commercial footprint comparable to IBSA's structure.

Broad incumbents

  • Viatris: Global generics and specialty pharma formed from Mylan and Upjohn, with broad off-patent portfolio that directly competes with IBSA's reformulation-led approach across multiple therapy areas.
  • Sandoz (Novartis): Global generics and biosimilars business carved out of Novartis, offering broad formulation expertise across therapy areas overlapping with IBSA's portfolio, but operating at much larger scale and global reach.
  • Teva Pharmaceutical Industries: Global generics and specialty leader with broad portfolio and large-scale manufacturing — competes with IBSA in formulation-improved generics and specialty pharma across overlapping therapy areas, but at vastly greater scale.

Regional players

  • Aspen Pharmacare: South African-headquartered specialty and generics pharma with emerging-market focus and broad therapeutic-area portfolio — comparable business model and scale to IBSA but primarily serves African and Asia-Pacific geographies rather than Europe/China/US.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Institut Biochimique social profiles

Digital presence

Institut Biochimique financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Institut Biochimique leadership team

Management profile

Number of profiles

Profiles1 record

Institut Biochimique subsidiaries and ownership

Company hierarchy

Subsidiaries18 records

Institut Biochimique funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Institut Biochimique M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut Biochimique

What does Institut Biochimique do?

IBSA (Institut Biochimique SA) is a multinational Swiss pharmaceutical company that develops, manufactures, and distributes formulation-optimized dosage forms of already known active ingredients across 10 therapeutic areas, including reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynecology, cardiometabolic medicine, respiratory treatments, and consumer health. The company produces its pharmaceutical products in Switzerland and sells them through 20 wholly-owned subsidiaries to customers in 90+ countries.

Is Institut Biochimique a public or private company?

Institut Biochimique is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Institut Biochimique founded?

Institut Biochimique was founded in 1945. It employs 101 to 250 people.

Where is Institut Biochimique based?

Institut Biochimique is headquartered in Lugano, Switzerland, in the Europe region.

How does Institut Biochimique make money?

One revenue line is on record: pharmaceutical Products.

Who are Institut Biochimique's main competitors?

Direct peers on record are Ferring Pharmaceuticals, Organon, Gedeon Richter, Almirall, Stada Arzneimittel and Recordati. Broad incumbents are Viatris, Sandoz (Novartis) and Teva Pharmaceutical Industries. Aspen Pharmacare is listed as a regional player.

Does Institut Biochimique have an API?

No public API is recorded for Institut Biochimique.

What industry is Institut Biochimique in?

Institut Biochimique's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAAAKAB, Drug Product Fill-Finish & Aseptic Manufacturing Services. Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNew Study Confirms That Novel Liquid Levothyroxine Solution Can be Administered as Early as 15 Minutes Before BreakfastA new study presented at the American Association of Clinical Endocrinology Annual Meeting found that IBSA Pharma Inc.'s liquid levothyroxine formulation, Tirosint-SOL, can be administered 15 minutes before breakfast without significantly affecting drug absorption or systemic availability, compared to the current FDA-mandated 30-60 minute wait time. The phase 1 bioavailability study tested 600 mcg doses in healthy volunteers fed an FDA-defined high-fat breakfast, with results showing similar drug exposure at both 15-minute and 30-minute pre-meal intervals. IBSA Institut Biochimique SA, the study sponsor, anticipates seeking FDA approval for a label change based on these findings, which researchers say could improve patient adherence to levothyroxine therapy.PR NewswireLannett Launches Authorized Generic of Tirosint® (Levothyroxine Sodium Capsules)Lannett Company, Inc. announced on November 3, 2020 the launch of an authorized generic version of Tirosint® (Levothyroxine Sodium Capsules) under an exclusive U.S. distribution agreement with IBSA Institut Biochimique SA of Switzerland. Lannett will handle sales, marketing, and distribution for the product, receiving a share of profits, and claims to be the sole provider of all 12 currently marketed dosage strengths for generic Levothyroxine Capsules. Total U.S. sales for the 12 months ended September 2020 were approximately $111 million according to IQVIA.PR NewswireLicart™ Now Available to Treat Acute Pain Due to Minor Strains, Sprains, and ContusionsIBSA Pharma Inc. announced the launch of Licart (diclofenac epolamine) topical system 1.3% in the US market for the treatment of acute pain due to minor strains, sprains, and contusions. Licart is the first and only FDA-approved once-a-day topical NSAID therapy, utilizing patented next-generation patch technology that provides pain relief within 1-3 hours and sustains it for 24 hours. The product is manufactured by IBSA Pharma, a fully-owned subsidiary of Switzerland-based IBSA Institut Biochimique SA, which positions this launch as an expansion of the company's topical pain therapy portfolio in the United States.site-ibsaIBSA goes global: new partnership in the US focused on fertilityIBSA announced a March 1 partnership with Boston-based Granata Bio to develop its subcutaneous progesterone in the US. The collaboration aims to address unmet fertility needs for patients using assisted reproductive technology. Both companies expressed commitment to patient safety and product efficacy.PR NewswireThe FDA has Approved Tirosint-SOL, Levothyroxine in Liquid Solution for the American Market, IBSA PatentThe FDA has approved Tirosint-SOL (levothyroxine sodium oral solution), a liquid formulation of the thyroid hormone developed by IBSA Institut Biochimique SA, for the US market to treat hypothyroidism and for TSH suppression in thyroid cancer management. The approval grants IBSA access to a market of 18 million patients estimated at $2 billion with 105 million prescriptions, with the product expected to be available within 6 months. The liquid formulation overcomes absorption interference issues common with tablet forms, eliminating the typical requirement to wait an hour before eating and allowing use for patients who cannot swallow or are fed by tube.PR NewswireFDA genehmigt Tirosint-SOL, Levothyroxin in flüssiger Lösung, für den amerikanischen Markt - Patent von IBSAIBSA Institut Biochimique SA announced that the US Food and Drug Administration (FDA) approved Tirosint-SOL (levothyroxine sodium oral solution), a liquid formulation of levothyroxine for treating hypothyroidism and TSH suppression in thyroid cancer patients. Clinical studies conducted in Italy demonstrated that the liquid form overcomes absorption limitations associated with traditional levothyroxine tablets, including interference from food, antacids, and conditions such as gastritis or lactose intolerance. The product, already marketed in Italy since 2012, is expected to launch in the US market within six months, targeting an estimated 18 million patients across a market valued at $2 billion with 105 million prescriptions.